Oncolytics Completes Patient Enrollment For Cancer Trial
Published: 02-Jul-2009
The study demonstrated a clinical benefit rate of 75%
Oncolytics has completed the patient enrolment in the phase II component of a phase I/II UK trial of Reolysin combined with paclitaxel/carboplatin. It is intended for patients with advanced cancers.
Interim results reported in March 2009, demonstrated that of 12 head and neck patients evaluable for clinical response, five had experienced a partial response and four had experienced stable disease ranging from two to six months, for a clinical benefit rate of 75%. Final results of the trial are expected to be released later this year.
Brad Thompson, President and CEO of Oncolytics, said: “This is an outstanding response rate in this difficult-to-treat patient population, and formed the basis of the Phase III pivotal program now being developed for Reolysin in combination with carboplatin/paclitaxel for head and neck cancer patients.”
Delicious
Digg
Reddit
Stumble
Facebook
LinkedInNetwork Sites
Mail sent successfully
Suppliers To This Sector
Browse A-Z
Almac
Drug Development Solutions ...
STARLIMS
Benefits for Life Science Labs ...
Parenteral Drug Association (PDA)
Pharmaceutical Information and Education Services ...
Burkert Fluid Control Systems
Fluid and Gas Control Systems ...
IMCOR
LIMS and Laboratory Informatics Consultancy ...
Umicore Precious Metals Chemistry
Chemicals and Catalysts for Industrial Applications ...
White Papers
Browse A-Z
CaseBase Management
BaseCon was established in 1999 to support the pharmaceutical sector with innovative IT so ...
SafetyBase Interchange
BaseCon was established in 1999 to support the pharmaceutical sector with innovative IT so ...
ClinicalBase Trial
BaseCon was established in 1999 to support the pharmaceutical sector with innovative IT so ...
Reliable Prediction of White Plasma Levels
Our kinetics & metabolism experts can help you select and further develop your candidate d ...
Kinetics and Metabolism
Our kinetics & metabolism experts can help you select and further develop your candidate d ...
Drug Safety Evaluation
Our kinetics & metabolism experts can help you select and further develop your candidate d ...
